Physician profile
Hyman Stadlen
NPI 1700924503
$5,297.64
in general payments reported to CMS, 2019-2025
23 companies · $406 in 2025
The $406 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $872 · 2020: $502 · 2021: $557 · 2022: $1,128 · 2023: $809 · 2024: $1,024 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,238.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,680.72 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $672.08 | 2019-2025 | Ozempic, Rybelsus |
| Lundbeck LLC | $359.81 | 2022-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $264.05 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $264.03 | 2019-2022 | |
| Pfizer INC. | $200.57 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $166.43 | 2024 | Rexulti |
| Lilly USA, LLC | $151.76 | 2019-2025 | Mounjaro, Zepbound |
| Mylan Specialty L.P. | $124.83 | 2023 | Yupelri |
| Exact Sciences Corporation | $80.12 | 2024 | Cologuard Collection Kit |
| Avanir Pharmaceuticals, INC. | $48.65 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.63 | 2022-2023 | |
| Amneal Pharmaceuticals LLC | $43.44 | 2021 | |
| Cmp Pharma, INC. | $24.12 | 2022 | |
| Kyowa Kirin, INC. | $23.28 | 2024 | Crysvita |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $22.59 | 2021 | |
| Boston Scientific Corporation | $22.16 | 2025 | Watchman Flx |
| Astellas Pharma US INC | $20.48 | 2021 | |
| Aimmune Therapeutics, INC. | $19.40 | 2025 | Vowst |
| Novartis Pharmaceuticals Corporation | $17.72 | 2019 | |
| Antares Pharma, INC. | $17.43 | 2023 | Nocdurna, Tlando, Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.81 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hyman Stadlen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.